Q-omics provides the consensus-scored RPS27P16 profile across patient tissues and cancer cell-line models. RPS27P16 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPS27P16 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RPS27P16 RNA expression shows 11,527 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight MESO, HNSC, and LAML as cancer lineages where RPS27P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS27P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS27P16 survival associations across molecular data types. RPS27P16 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS27P16 RNA expression–survival associations across cancer types. High RPS27P16 expression shows unfavorable associations in THYM, PCPG and LGG, but favorable associations in MESO, ACC and SARC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .012). Together, the overview and detailed table identify MESO as the clearest survival context for RPS27P16 RNA expression.
This table summarizes RPS27P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS27P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS27P16 shows lower tumor expression in COAD and higher tumor expression in HNSC, BLCA, KICH, LUSC and ESCA. The HNSC box plot shows higher RPS27P16 RNA expression in tumor versus normal tissue (log2 FC = +2.348, t-test p < 0.001).
This table shows molecular features associated with RPS27P16 in patient tissues and cancer cell lines. In patient samples, RPS27P16 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
